{"nctId":"NCT00092417","briefTitle":"Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)","startDateStruct":{"date":"2003-10"},"conditions":["Healthy"],"count":695,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Varicella Zoster Virus Vaccine"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Varicella Zoster Virus Vaccine"]}],"interventions":[{"name":"Comparator: Varicella Zoster Virus Vaccine","otherNames":[]},{"name":"Comparator: Varicella Zoster Virus Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy individuals 50 years of age or older with a history of chickenpox who have not had herpes zoster\n\nExclusion Criteria :\n\n* Preexisting conditions that might affect vaccine safety such as conditions that inhibit an immune response","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Vaccine-related Serious Clinical Adverse Experiences (SAEs)","description":"The incidence of vaccine-related SAEs occurring Day 1 through Day 42 postvaccination. Whether a serious clinical adverse experience occurring Day 1 through Day 42 postvaccination was vaccine-related was determined by the investigator who was a qualified physician . The difference in the risk of developing a vaccine-related SAE between the two groups was compared at the 2-sided 0.05 level.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"459","spread":null},{"groupId":"OG001","value":"234","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling (> 2 Inches at Largest Diameter)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"380","spread":null},{"groupId":"OG001","value":"213","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Varicella or Varicella-like Noninjection-site Rashes, Nondermatomal in Distribution With >100 Lesions","description":"Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be varicelliform rash by the study physician and polymerase chain reaction (PCR).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"459","spread":null},{"groupId":"OG001","value":"234","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Herpes Zoster (HZ) or HZ-like Rashes","description":"Noninjection-site rash Day 1 through Day 42 postvaccination was reported by the participant to the investigator and confirmed to be zosteriform rash by the study physician and polymerase chain reaction (PCR).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"456","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Fevers ≥101.0°F [≥38.3°C]","description":"Maximum reported oral or equivalent temperature ≥101.0°F \\[≥38.3°C\\] was reported Day 1 through Day 21 postvaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"452","spread":null},{"groupId":"OG001","value":"229","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":459},"commonTop":["Injection Site Erythema","Injection Site Pain","Injection Site Swelling","Injection Site Pruritus","Headache"]}}}